77 related articles for article (PubMed ID: 2033965)
1. DNA fingerprinting in the detection of residual disease in acute leukemia.
Pakkala S
Leukemia; 1991 May; 5(5):437-40. PubMed ID: 2033965
[TBL] [Abstract][Full Text] [Related]
2. Leukemia-associated phenotypes: their characteristics and incidence in acute leukemia.
Babusíková O; Glasová M; Koníková E; Kusenda J
Neoplasma; 1996; 43(6):367-72. PubMed ID: 8996560
[TBL] [Abstract][Full Text] [Related]
3. Implications of detection of minimal residual disease.
Wörmann B
Curr Opin Oncol; 1993 Jan; 5(1):3-12. PubMed ID: 8427891
[TBL] [Abstract][Full Text] [Related]
4. Monitoring of relapse and remission in acute leukaemias by DNA-fingerprint analysis.
Hübner G; Battmer K; Paaz U; Link H
Br J Haematol; 1993 Oct; 85(2):320-5. PubMed ID: 8280604
[TBL] [Abstract][Full Text] [Related]
5. DNA-fingerprint changes compared to karyotypes in acute leukemia.
Pakkala S; Knuutila S; Helminen P; Ruutu T; Saarinen UM; Peltonen L
Leukemia; 1990 Dec; 4(12):866-70. PubMed ID: 2243509
[TBL] [Abstract][Full Text] [Related]
6. [Role of molecular genetic investigations in the diagnosis of acute leukemias and in the detection of minimal residual disease].
Földi J; Páldi HP; Nahajevszky S; Jakab K; Regéczi N; Pálóczi K
Orv Hetil; 2001 May; 142(21):1097-102. PubMed ID: 11449838
[TBL] [Abstract][Full Text] [Related]
7. [Various aspects of bone marrow cell proliferation in acute leukemia].
Shmarov DA; Kuchma IuM; Kozinets GI
Ter Arkh; 2001; 73(12):73-7. PubMed ID: 11858117
[TBL] [Abstract][Full Text] [Related]
8. Detection of residual disease in AML patients by use of double immunological marker analysis for terminal deoxynucleotidyl transferase and myeloid markers.
Adriaansen HJ; Jacobs BC; Kappers-Klunne MC; Hählen K; Hooijkaas H; van Dongen JJ
Leukemia; 1993 Mar; 7(3):472-81. PubMed ID: 7680403
[TBL] [Abstract][Full Text] [Related]
9. [Immunophenotypic and immunogenotypic analyses of acute leukemia and lymphoblastic lymphoma expressing myeloid and lymphoid antigens].
Kawamura K; Tobinai K
Rinsho Byori; 1992 Jul; 40(7):761-8. PubMed ID: 1507495
[TBL] [Abstract][Full Text] [Related]
10. P53 protein expression in human leukemia and lymphoma cells.
Koníková E; Kusenda J
Neoplasma; 2001; 48(4):290-8. PubMed ID: 11712681
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease in childhood acute lymphoblastic leukemia: analysis of patients in continuous complete remission or with consecutive relapse.
Biondi A; Yokota S; Hansen-Hagge TE; Rossi V; Giudici G; Maglia O; Basso G; Tell C; Masera G; Bartram CR
Leukemia; 1992 Apr; 6(4):282-8. PubMed ID: 1316978
[TBL] [Abstract][Full Text] [Related]
12. Residual disease detection in multiple follow-up samples in children with acute lymphoblastic leukemia.
Kitchingman GR
Leukemia; 1994 Mar; 8(3):395-401. PubMed ID: 8127144
[TBL] [Abstract][Full Text] [Related]
13. Prospective application of a multiplex reverse transcription-polymerase chain reaction assay for the detection of balanced translocations in leukaemia: a single-laboratory study of 390 paediatric and adult patients.
Olesen LH; Clausen N; Dimitrijevic A; Kerndrup G; Kjeldsen E; Hokland P
Br J Haematol; 2004 Oct; 127(1):59-66. PubMed ID: 15384978
[TBL] [Abstract][Full Text] [Related]
14. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia.
Roberts WM; Estrov Z; Ouspenskaia MV; Johnston DA; McClain KL; Zipf TF
N Engl J Med; 1997 Jan; 336(5):317-23. PubMed ID: 9011783
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
Cavé H; van der Werff ten Bosch J; Suciu S; Guidal C; Waterkeyn C; Otten J; Bakkus M; Thielemans K; Grandchamp B; Vilmer E
N Engl J Med; 1998 Aug; 339(9):591-8. PubMed ID: 9718378
[TBL] [Abstract][Full Text] [Related]
16. A method comparison study of flow cytometry and cytomorphology to determine the percentages of blasts in patients with acute leukemia after induction and consolidation chemotherapy.
Wongprajun S; Auewarakul CU
J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S157-64. PubMed ID: 20364570
[TBL] [Abstract][Full Text] [Related]
17. Pattern of T-cell receptor delta gene rearrangement by Southern blotting and polymerase chain reaction technique in Hong Kong Chinese patients with non-T-cell hematological malignancies.
Chan DW; Liang R; Kwong YL
Hematol Oncol; 1996 Jun; 14(2):57-66. PubMed ID: 8876635
[TBL] [Abstract][Full Text] [Related]
18. Leukemia-associated marker combinations in acute leukemia suitable for detection of minimal residual disease.
Babusíková O; Mesárosová A; Koníková M; Kusenda J; Glasová M; Klobusická M
Neoplasma; 1993; 40(5):275-81. PubMed ID: 8272155
[TBL] [Abstract][Full Text] [Related]
19. Qualitative assessment of mixed chimerism after allogeneic bone marrow transplantation with regard to leukemic relapse.
Kögler G; Hernandez A; Heyll A; Wolf HH; Wernet P
Cancer Detect Prev; 1996; 20(6):601-9. PubMed ID: 8939346
[TBL] [Abstract][Full Text] [Related]
20. Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation.
Seriu T; Yokota S; Nakao M; Misawa S; Takaue Y; Koizumi S; Kawai S; Fujimoto T
Leukemia; 1995 Apr; 9(4):615-23. PubMed ID: 7723394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
